Stocks and Investing Stocks and Investing
Thu, July 8, 2021
Wed, July 7, 2021
Tue, July 6, 2021
Mon, July 5, 2021
Fri, July 2, 2021
Thu, July 1, 2021
Wed, June 30, 2021
Tue, June 29, 2021

David Nierengarten Maintained (BEAM) at Buy with Increased Target to $149 on, Jun 29th, 2021


Published on 2024-10-27 17:05:03 - WOPRAI, David Nierengarten
  Print publication without navigation


David Nierengarten of Wedbush, Maintained "Beam Therapeutics Inc." (BEAM) at Buy with Increased Target from $114 to $149 on, Jun 29th, 2021.

David has made no other calls on BEAM in the last 4 months.



There are 2 other peers that have a rating on BEAM. Out of the 2 peers that are also analyzing BEAM, all agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Initiated at Hold and Held Target at $85 on, Tuesday, May 4th, 2021
  • Gena Wang of "Barclays" Downgraded from Buy to Hold and Increased Target to $90 on, Monday, March 1st, 2021